Asia Firms Tweak Strategy Amid Biosimilars ‘Stampede’
This article was originally published in PharmAsia News
Executive Summary
More biosimilar approvals for Asian firms in western markets, building on the success of major players like Celltrion and Samsung, and a shift away from local/regional development strategies, were some of the key trends in the sector highlighted at a recent roundtable in India.